We're proud to announce the submission of a Biologics License Application (BLA) to the @US_FDA for our investigational treatment option for children ages 4 through 7 with peanut allergy. Learn more here: bit.ly/47q97SC

This September, we will be participating in three investor conferences: ➡️ Cantor Fitzgerald Global Healthcare Conference – Fireside Chat on Wednesday, September 9. ➡️ Citi’s 2026 Biopharma Back to School Conference – 1 on 1 Meetings on Thursday, September 10. ➡️ H.C. Wainwright & Co. Global Investment Conference – Fireside Chat on Tuesday, September 15. We're grateful for these opportunities to engage with investors and industry peers and we look forward to sharing updates on our regulatory and commercial progress. For details: bit.ly/4hbhzLe

Every day, our team works to change what care could look like for children living with food allergies. Our efforts are grounded in science and shaped by the needs of patients and their families. Explore opportunities to join us: bit.ly/3Hk9uF0

For most families, back-to-school season means new supplies and new routines. Managing a child's food allergy means a lot of extra planning: briefing teachers, coordinating with cafeteria staff, packing safe lunches, and reviewing every label, all before the first bell rings. Peanut allergy in particular can restrict daily activities and create ongoing worry for children and their families, including concerns about school. At DBV, this is part of why we do what we do — we're committed to advancing options that could potentially help ease this burden. To every family gearing up for the school year: we see the planning, the vigilance, and the care you put in. We're with you. Learn more about our mission: bit.ly/47yp7Bs

This August, we’re heading to three regional allergy conferences: - New York Allergy & Asthma Society (NYAAS) - Alabama Society of Allergy, Asthma and Immunology (ASAAI) - American Society of Allergy Professionals (ASAP) Through these engagements, we look forward to our continued dialogue with state-level allergy societies as we advance our commitment to addressing the significant unmet medical need in pediatric allergy care. Visit our booth to learn more!

At the center of our approach to food allergy management is epicutaneous immunotherapy (EPIT); a differentiated mechanism of action that uses the skin as the entry point for immune modulation. As the body's largest immunologic organ, the skin plays an important role in shaping immune responses. EPIT harnesses the immune properties of the skin to help induce desensitization while limiting systemic allergen exposure. At DBV, we’re working to advance this non-invasive and innovative approach to food allergy management, because patients and families deserve more options. Learn more about our science: bit.ly/4b5svUE

Timing can change everything in food allergy care. In the earliest years of life, the immune system is remarkably adaptable. This creates a critical window of opportunity when early diagnosis and intervention may help re-educate the immune system before allergic patterns become firmly established. Peanut allergy often begins in infancy and typically persists throughout life. That’s why continued research in younger children is so important. At DBV, we’re advancing an innovative approach that harnesses the powerful immune properties of the skin – the body’s largest immunologic organ – to potentially desensitize children to allergens over time. Evidence has shown the strongest benefit when treatment is started earlier and continued long term. 🔗 Learn more about our science: bit.ly/4fWxxFk

We're looking forward to joining clinicians, researchers, and healthcare leaders in Colorado this week for the 2026 Annual Aspen Allergy Conference. This meeting provides an important opportunity to connect with experts in the field to discuss the latest advances shaping the future of allergy care. We're excited to be a part of the conversations around emerging potential treatment options and the continued progress for patients and families living with food allergies. Learn more about the conference here: bit.ly/44Gqb5K

The team behind DBV brings more than scientific expertise; they also bring personal connections to the food allergy community. Mary Hawkins, Medical Science Liaison at DBV Technologies, was a practicing pediatric allergy nurse before joining our team. The experiences she had with children and families living with food allergies don't just inform her work, they inspire it. For Mary, and for many of us at DBV, this mission is personal. Learn more about us here: bit.ly/47yp7Bs

Today, we reported our second quarter and half-year 2026 financial results. These reflect important progress toward our BLA submission for the investigational VIASKIN® Peanut Patch in children 4 through 7 years and advancements across our toddler and infant clinical programs, with funding to support operations and commercial preparedness into Q3 2027. We remain focused on advancing DBV into its next phase, driven by our commitment to making a meaningful difference for children and families living with food allergies. Today at 5:00 PM ET, we will host a conference call and live webcast. Participants may join the call via telephone: 📞United States: +1-877-344-8082 📞International: +1-213-992-4618 The live webcast will also be available on the Events section of our website.➡️Tune in to learn more: bit.ly/4gDyzKo For additional information, read our full press release: bit.ly/3ToaJsl

At DBV, we understand that living with peanut allergy doesn't look the same for everyone. That’s why we’re proud to advance a proactive, patient-centric approach to peanut allergy management that meets patients and families where they are on their journey. ​ Recently at the @EAACI_HQ Congress 2026, we previewed our newly initiated Phase 2 THRIVE open-label study assessing ad lib consumption of peanut in infants ages 6 through 12 months with peanut allergy treated with epicutaneous immunotherapy.​ THRIVE is quintessential DBV. It is a reflection of our commitment to the food allergy community and a bold next step toward meaningful progress, where early intervention may help shape long-term outcomes. Learn more in our press release: bit.ly/4vHyGsN

This summer, the DBV team went to Camp TAG, hosted by FAACT, a dedicated space where children with food allergies can experience the full joy of summer camp and just be kids; something that can feel out of reach for families navigating strict avoidance every day. These experiences are a meaningful reminder of the children and families at the heart of our commitment to advance #FoodAllergy care. We’re proud to support the organizations helping create safe, welcoming spaces for this community – because life should be bigger than food allergies. Learn more about our mission: bit.ly/47yp7Bs

We are pleased to announce that DBV Technologies has been included in the Euronext Tech Leaders index, recognizing leading business for their innovation, growth trajectory, and contribution to the European technology ecosystem. We believe this inclusion reflects the strength of our scientific programs and our progress in advancing pediatric #FoodAllergy care. Read the full press release to learn more: bit.ly/3Sl8fe1

Behind every advancement in #FoodAllergy care are people driven by purpose. Chalise, Senior Director, Clinical Supply Chain, understands the impact food allergies can have on how children and families navigate the world, and the vigilance they require in everyday life. Joining DBV has deepened her respect for these families and her commitment to bringing them hope. That perspective fuels a more driven, intentional approach to our work as we advance research that could make a meaningful difference in food allergy care. Learn more about the people behind our mission: bit.ly/4vvfw9G

We look forward to connecting with the food allergy community at @EAACI_HQ Congress 2026, where we will share: ➤ A subgroup analysis of children ages 4 through 7 with peanut allergy and atopic comorbidities from our Phase 3 VITESSE study. ➤ A preview of our newly initiated Phase 2 THRIVE open-label study assessing the ad lib consumption of peanut in infants ages 6 through 12 months with peanut allergy treated with epicutaneous peanut immunotherapy. Across age groups, we are proud to advance a proactive, patient-centric approach to peanut allergy management that meets patients where they are on their journey. Read more in our press release: bit.ly/4vHyGsN #EAACICongress2026

What if your work could help change the future of pediatric food allergy care? At DBV, our team is fueled by curiosity, strengthened by collaboration, and grounded in scientific credibility. Together, we are working to imagine a world where food allergies and immunological conditions are treated safely, effectively, and with greater care for children and their families. Explore opportunities to join us: dbv-technologies.com/careers…

A proud moment for our team! We were featured on the @Nasdaq Tower for #FoodAllergyAwarenessWeek; a meaningful reminder of the families we aim to serve. We’re dedicated to advancing pediatric #FoodAllergy care and supporting our community every step of the way. Discover more about our mission: bit.ly/3S6OALw #FAAW2026

Our team is coming together in teal to show support for the food allergy community. Behind our work are people with lived experiences and personal connections, as parents, physicians, advocates, and individuals who understand the impact food allergies can have on everyday life. We understand firsthand how food allergies may be unseen but should never be unnoticed. Sharing these perspectives is one way we continue to build awareness and strengthen our mission of advancing pediatric #FoodAllergy care. Learn more about our team and commitment: bit.ly/47yp7Bs #FAAW2026

May is #FoodAllergyAwarenessMonth! For millions of families, food allergy is more than a diagnosis, it is a daily reality that requires constant awareness, preparation, and care. This month, we’re highlighting the importance of education, advocacy, and continued progress in pediatric food allergy care. At DBV Technologies, we’re proud to work alongside organizations to create a future where children and families can navigate food allergies with confidence. Learn more from our advocacy partners: @AllergyAsthmaHQ, @AAFA_Advocacy, @FoodAllergy, FAACT and @FoodAllergyCAN.

Today, we reported first quarter 2026 financial results. Read the full press release here: dbv-technologies.com/press_r…